References
- Chiesi LimitedTrimbow 87 Micrograms/5 Micrograms/9 Micrograms Pressurised Inhalation, Solution: Summary of Product CharacteristicsManchester, UK2017
- SinghDSchröder-BaboWCohuetGTRIDENT Study InvestigatorsThe bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: a randomised crossover study (the TRIDENT study)Respir Med2016114849027109816
- SinghDScuriMCollariniSBronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 studyInt J Chron Obstruct Pulmon Dis2017122001201428744115
- RootmensenGNvan KeimpemaARJJansenHMde HaanRJPredictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring methodJ Aerosol Med Pulm Drug Deliv201023532332820804428
- VirchowJCCromptonGKDal NegroRImportance of inhaler devices in the management of airway diseaseRespir Med20081021101917923402
- FarkasÁLewisDChurchTExperimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler® dry powder inhalerInt J Pharm2017533122523528941830
- O’DonnellDEEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
- BeehKMWatzHPuente-MaestuLAclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trialBMC Pulm Med201414120925539654
- ArievichHOverendTRenardDA novel model-based approach for dose determination of glycopyrronium bromide in COPDBMC Pulm Med20121217423217058
- LeakerBRBarnesPJJonesCRTutuncuASinghDEfficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary diseaseBr J Clin Pharmacol201579349250025243340
- SinghDRaviAReidFBuckHO’ConnorGDownGBronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover studyPulm Pharmacol Ther20163791426827913
- AgustiACalverleyPMACelliBEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
- VestboJAndersonJABrookRDFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182627203508
- TashkinDPCelliBDecramerMBronchodilator responsiveness in patients with COPDEur Respir J200831474275018256071
- CazzolaMMacNeeWMartinezFJAmerican Thoracic SocietyEuropean Respiratory Society Task Force on Outcomes ofCOPDOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
- VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
- SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678